BioLineRx Ltd.
19 Hartum Street
P.O. Box 45158
Jerusalem 91450
Tel: 972-2-548-9100
Fax: 972-2-548-9101
Website: http://www.biolinerx.com/
Email: info@BioLineRx.com
424 articles about BioLineRx Ltd.
-
BioLineRx to Report Annual 2020 Results on February 23, 2021
2/17/2021
BioLineRx Ltd. (NASDAQ: BLRX) (TASE: BLRX), a late clinical-stage biopharmaceutical company focused on oncology, announced today it will release its audited financial results for the year ended December 31, 2020 on Tuesday, February 23, 2021
-
BioLineRx Increases Previously Announced Bought Deal Offering to $30 Million
1/20/2021
BioLineRx Ltd. announced that due to demand, the underwriter has agreed to increase the size of the previously announced offering and purchase on a firm commitment basis 12,500,000 American Depositary Shares of the Company, at a price to the public of $2.40 per ADS, less underwriting discounts and commissions.
-
BioLineRx Announces $10 Million Bought Deal Offering
1/19/2021
BioLineRx Ltd. (NASDAQ: BLRX) (TASE: BLRX), a late clinical-stage biopharmaceutical company focused on oncology, today announced that it has entered into an underwriting agreement with H.C. Wainwright & Co., LLC under which the underwriter has agreed to purchase on a firm commitment basis 4,166,667 American Depositary Shares
-
BioLineRx Announces Final Results from Phase 2a COMBAT/KEYNOTE-202 Triple Combination Study of Motixafortide in Second Line Metastatic Pancreatic Cancer (PDAC)
12/16/2020
Company to host Key Opinion Leader (KOL) webinar to discuss these results today, December 16, at 8:00 am EST; registration link below
-
BioLineRx to Report Third Quarter 2020 Results on November 23, 2020
11/18/2020
BioLineRx Ltd. (NASDAQ: BLRX) (TASE: BLRX), a late clinical-stage biopharmaceutical company focused on oncology, announced today it will release its unaudited financial results for the quarter ended September 30, 2020 on Monday, November 23, 2020 , befor
-
BioLineRx Announces Initiation of Phase 1b Clinical Trial in Patients with Acute Respiratory Distress Syndrome (ARDS) Secondary to COVID-19 and Other Respiratory Viral Infections
11/18/2020
- Investigator-initiated study, led by Wolfson Medical Center, to evaluate Motixafortide in up to 25 patients hospitalized with ARDS - - Results of preliminary analysis expected in H1 2021-
-
BioLineRx Announces Positive Results from Interim Analysis of GENESIS Phase 3 Trial of Motixafortide (BL-8040) in Stem Cell Mobilization
10/30/2020
Enrollment to cease immediately; topline data anticipated in H1 2021
-
BioLineRx Announces Initiation of Phase 2 Clinical Trial in First-Line Metastatic Pancreatic Cancer
10/29/2020
- Investigator-initiated Phase 2 study, led by Columbia University, to evaluate Motixafortide in combination with LIBTAYO® and chemotherapy in first-line metastatic pancreatic ductal adenocarcinoma -
-
BioLineRx Achieves Enrollment Target in Phase 3 GENESIS Trial for Planned Interim Analysis
8/19/2020
BioLineRx Ltd., a late clinical-stage biopharmaceutical company focused on oncology, announced that a sufficient number of patients have been enrolled in the ongoing GENESIS Phase 3 trial to allow for an interim efficacy analysis to take place in the second half of 2020.
-
BioLineRx Reports Second Quarter 2020 Financial Results and Provides Corporate Update
8/6/2020
- On track to report three significant data readouts in next few months - - Completes successful financings, raising gross proceeds of $13.4 million; sufficient to reach multiple important milestones - - Management to hold conference call today, August 6, at 10:00 am EDT - [06-August-2020] TEL AVIV, Israel , Aug. 6, 2020 /PRNewswire/ -- Bi
-
BioLineRx to Report Second Quarter 2020 Results on August 6, 2020
7/31/2020
BioLineRx Ltd., a late clinical-stage biopharmaceutical company focused on oncology, announced it will release its unaudited financial results for the quarter ended June 30, 2020 on Thursday, August 6, 2020, before the US markets open.
-
BioLineRx Announces $4.39 Million Registered Direct Offering
6/1/2020
BioLineRx Ltd. (NASDAQ: BLRX) (TASE: BLRX), a late clinical-stage biopharmaceutical company focused on oncology, today announced that it has entered into definitive agreements with several healthcare-focused, institutional and accredited investors for the purchase and sale of 2,510,286 of the Company's American Depositary Shares (ADS
-
BioLineRx Announces Publication of Data from Ongoing COMBAT/KEYNOTE-202 Clinical Trial in Nature Medicine
5/27/2020
BioLineRx Ltd. (NASDAQ: BLRX) (TASE: BLRX), a clinical-stage biopharmaceutical Company focused on oncology, today announced that a paper, entitled 'BL-8040, a CXCR4 Antagonist, in Combination with Pembrolizumab and Chemotherapy for Pancreatic Cancer: The COMBAT Trial,' has been published in the peer-reviewed journal Nature Medicine
-
BioLineRx Announces $9.0 Million Registered Direct Offering
5/26/2020
BioLineRx Ltd. (Nasdaq: BLRX) (TASE: BLRX), a late clinical-stage biopharmaceutical company focused on oncology, today announced that it has entered into definitive agreements with several healthcare-focused, institutional and accredited investors for the purchase and sale of 5,142,859 of the Company's American Depositary Shares (ADSs
-
BioLineRx Reports First Quarter 2020 Financial Results and Provides Corporate Update
5/20/2020
On track to report progression free survival and overall survival data from triple combination arm of ongoing COMBAT/KEYNOTE-202 Phase 2a trial in mid-2020
-
BioLineRx to Report First Quarter 2020 Results on May 20, 2020
5/15/2020
BioLineRx Ltd. (NASDAQ: BLRX) (TASE: BLRX), a late clinical-stage biopharmaceutical company focused on oncology, announced today it will release its unaudited financial results for the quarter ended March 31, 2020 on Wednesday, May 20, 2020 , before
-
BioLineRx Reports Year-End 2019 Financial Results and Provides Corporate Update
3/12/2020
- On track to report progression free survival and overall survival data from triple combination arm of ongoing COMBAT/KEYNOTE-202 Phase 2a trial in mid-2020 -
-
BioLineRx to Report Annual 2019 Results on March 12, 2020
3/6/2020
BioLineRx Ltd. (NASDAQ: BLRX) (TASE: BLRX), a late clinical-stage biopharmaceutical company focused on oncology, announced today it will release its audited financial results for the year ended December 31, 2019 on Thursday, March 12, 2020, before the US markets open.
-
BioLineRx Announces Notice of Allowance from USPTO for Patent Covering Motixafortide (BL-8040) in Combination With Anti-PD-1 for the Treatment of Any Type of Cancer
2/27/2020
BioLineRx Ltd. (NASDAQ: BLRX), (TASE: BLRX), announced today that a Notice of Allowance has been issued by the United States Patent and Trademark Office (USPTO) for a patent application claiming the use of motixafortide (BL-8040), a novel immunotherapy compound
-
BioLineRx Completes Recruitment in Triple Combination Arm of COMBAT/KEYNOTE-202 Study in Patients With Second-line Metastatic Pancreatic Cancer
1/22/2020
BioLineRx Ltd. (NASDAQ: BLRX) (TASE: BLRX), a clinical-stage biopharmaceutical company focused on oncology, announced today the completion of patient recruitment in the triple combination arm of its ongoing Phase 2a COMBAT/KEYNOTE-202 study.